Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With...

Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI
With Regard to Patents Held by AGA Medical

JENA, Germany, April 17 /PRNewswire/ -- Occlutech GmbH, the leading
European manufacturer of cardiac occlusion devices today announced a
clarification of a recent news release.
In a news release dated February 8th, 2008, Occlutech stated that it
received an opinion from AIPPI the European "Association for the Protection
of Intellectual Property" with regard to non infringement by Occlutech of
certain European IP held by AGA Medical.
AIPPI has requested a clarification of this statement:
1) The name European International Association for the Protection of
Intellectual Property was not stated correctly. The correct name is the
"International Association for the Protection of Intellectual Property".
2) The opinion received by Occlutech which states that Occlutech is not
infringing EP 0808138B1 and its Italian part 019020BE/2006 held by AGA
Medical Corp was commissioned through the Italian National Group of AIPPI but
not issued by AIPPI International itself. The opinion was issued by and in
the name of three independent experts nominated by the Italian Group of
AIPPI. The opinion was issued by the experts nominated by the Italian Branch
of AIPPI and not by, in the name of or on behalf of AIPPI International or
the Italian National Group of AIPPI.
The opinion was given without influence of Occlutech GmbH and the
impartiality of the experts has subsequently been confirmed by the Italian
Branch of AIPPI.
3) Such an independent opinion commissioned through AIPPI is an
instrument aiming at giving the requiring party a qualified and impartial
opinion. It does not represent an official opinion by AIPPI since AIPPI does
not get involved in intellectual property disputes between parties on behalf
or in favour of one of the parties.
Occlutech GmbH regrets that its communication was not clear with regard
to the role of AIPPI in commissioning and receiving the opinion.
Occlutech GmbH develops and manufactures a wide range of occluders that
are sold under the Occlutech Figulla N brand in over 40 countries in European
and international markets. Clinical programs leading to regulatory approval
in the US and Japan are underway.
Contact:
Robert Moszner
e-mail: robert.moszner@occlutech.com
Phone: +49-3641-67-51-20

Susanne Goransson
e-mail: info@occlutech.info
Phone: +46-704336521

SOURCE Occlutech GmbH

Contact: Robert Moszner, e-mail: robert.moszner@occlutech.com, Phone:
+49-3641-67-51-20. Susanne Goransson, e-mail: info@occlutech.info, Phone:
+46-704336521